How common is sarcopenia (loss of muscle) in people with type 2 diabetes – and what can we do about it?
To pin down exactly how common sarcopenia is, is challenging, because doctors are often not...
Read More
Category: Diabetes
Update: Can GLP1 medications cause loss of vision (NAION)?
While clinical trials of GLP1 medications [semaglutide (Ozempic/Wegovy), tirzepatide...
Read More
GLP-1 in a pill for weight loss – pinning down where we’re at
While we now have several injectable GLP-1 based treatments available for weight management around...
Read More
Does everyone with type 2 diabetes need to be screened for MASH/MASLD (‘fatty liver’)? What the new Diabetes Canada Guidelines recommend
As blogged previously, metabolic dysfunction-associated steatotic liver disease (MASLD) and...
Read More
How does Mounjaro stack up for cardiovascular protection? The SURPASS CVOT results
In choosing the best GLP1-based medication for our patients with type 2 diabetes at high risk of...
Read More
Wegovy Plus Amylin: CagriSema weight management results revealed!
Our natural human biology vigourously defends our body weight, in part because we have many...
Read More
Could risk of heart attack and stroke risk rise decades before type 2 diabetes diagnosis?
Diabetes is a risk factor for cardiovascular (CV) disease. We know that diabetes itself increases...
Read More
The hidden disease: Peripheral artery disease (and what we can do about it)
In our quest to look for and treat cardiovascular disease, healthcare professionals typically...
Read More
First GLP1 in a pill to reduce cardiovascular events in people with type 2 diabetes
We know that several GLP1 receptor agonists reduce cardiovascular events in people with type 2...
Read More
When you take weight loss medication, which other medications may need adjusting?
When taking weight management medication, it’s important not to overlook the impact this can...
Read More
Can Diabetic Retinopathy (Eye complications) Lead to Sleepless Nights?
Diabetic retinopathy (DR) is a common complication of diabetes, affecting the eyes and potentially...
Read More
Do GLP1-based weight management/diabetes medications need to be held before anesthesia or sedation? New guidance
As blogged previously here and here, much controversy exists as to whether, when, in whom, or for...
Read More
Dr. Sue Pedersen
I am a medical doctor, Specialist in Endocrinology & Metabolism, a Diplomate of the American Board of Obesity Medicine, and a Clinical Lecturer at the University of Calgary, Canada. After completing my training as an Endocrinologist in 2005 at the University of Calgary, I have worked in Calgary, at the Royal University Hospital in Saskatchewan, and at the University of Copenhagen in Denmark. I have a busy clinical practice at C-ENDO Diabetes and Endocrinology Clinic in Calgary, caring for patients with diabetes, obesity, thyroid, and other hormone issues. I am also involved in clinical research in diabetes and obesity. I am the lead author of the 2020 and 2022 Pharmacotherapy Chapters of the Canadian Obesity Clinical Practice Guidelines, and a member of the Expert Committee for the Diabetes Canada Clinical Practice Guidelines as an author on the Weight Management chapter. I am passionate, enthusiastic, and driven to help conquer the stigma against obesity; educate health care professionals and the public about obesity and diabetes; and to help us become a healthier society!
